About Us

We bring together innovators and investors to commercialise the companies that will form the longevity economy.

There are already 100+ rejuvenation biotechs working on unique therapies and building R&D pipelines to increase healthspan and lifespan.

At the same time, all around the world, innovators are releasing nanobots, reprogramming nerve signals and applying AI to create exciting and scalable contributions to human Longevity.

Longevity science is here; so are the risks and so are the rewards.

We look beyond rejuvenation therapies to embrace other technologies that participate in the Longevity investment category: Agetech, xeno, biomarkers, AI, bioprinting, neuroceuticals, GRAS supplements …

There are multiple technologies that contribute to the reduction of morbidity and the extension of lifespan.

Executive team

Phil Newman

Founder & CEO

Phil is a seasoned marketing and business development professional. He is also Editor-in-Chief of Longevity.Technology and oversees content strategy, market research, and deal-flow.

In his career, Phil has held c-level management positions across multiple tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

George Sutherland

Non-exec Chairman

In over 30 years of experience in health markets, George has demonstrated many years of success working with major fast moving consumer goods (FMCG) and medical companies.

He as pre and post IPO experience, operating as a non-executive chairman for start-ups in health tech: First Longevity; Trueinvivo; TestCard.

Tom Britton

Non-exec Director

After completion of an MBA at Cambridge Tom co-founded SyndicateRoom – a data driven Venture Capital fund which has gone-on to be a leading platform in UK investment

His invaluable skills include: Early-stage Venture Finance, Product Development, Project / Program Management, Data Analysis, Process Implementation, and managing startups.

Advisory panel

Jim Mellon

Chairman & Founder,
Burnbrae Group, Juvenescence

Aubrey de Grey

Non-exec Chairman

George Church

Founding Core Faculty & Lead, Synthetic Biology, Harvard University

Biotech AgeX Therapeutics reported financial and commercialises its stem cell lines, but continues to borrow from stakeholder Juvenescence.

Greg Bailey


Alexander Zhavoronkov

Chief Executive Officer Insilico Medicine, Inc

Lorraine Morley

UK Lead / Advisor,
AgeTech Accelerator

Michael Hufford

Co-Founder and CEO,

João Pedro de Magalhães

Professor Institute of Ageing and Chronic Disease University of Liverpool


Eleanor Garth

Deputy Editor

Danny Sullivan

Contributing Editor

Daragh Campbell

Head of Research

Dev Heaton

Marketing and Design Manager

Laura Allison

Marketing Executive

Harriet Grantham

Marketing Executive

Victoria Barros Metlova

Staff Writer

We are looking for ambitious
Longevity startups and investors